Our mission
Since our inception in 2011, our mission is to empower individuals by creating advanced, home-use photobiomodulation technology while also driving scientific breakthroughs.
As pioneers in the field of brain and systemic photobiomodulation, we made our groundbreaking technology available to people for more than a decade, to thousands of users.
Our commitment to innovation has resulted in the development of patented technology that has shown efficacy in independent pilot and clinical trials for devastating conditions.
Through our steadfast dedication to collaborative research with the brightest minds, our technology has accumulated the most published studies and ongoing clinical trials on a global scale.

Who we are
The technology of Vielight dates back to 1995 in the Silicon Valley – when the founders, Dr. Lew Lim and a group of engineers explored the potential of intranasal photobiomodulation. Intranasal photobiomodulation devices were commercially developed in 2003, which were later trademarked as “Vielight” when the company was incorporated in 2011.
Over the years, our focus shifted towards the development of unique photobiomodulation devices which enhance cognition and performance, among other things.
Today, our team has since evolved into a formidable team of engineers, scientists and business professionals dedicated to bringing the technology to as many people as possible.

Our dedication to research
Attaining our goal of helping people through photobiomodulation would not be possible without the right people. That is why Vielight have gathered many bright minds from a diverse range of scientific backgrounds to continuously improve the efficacy of brain and systemic photobiomodulation technology.
We appreciate and recognize our esteemed research collaborators:
• Reza Zomorrodi, PhD (Temerty Centre for Therapeutic Brain Intervention at CAMH, University of Toronto)
• Margaret Naeser, PhD (Boston University School of Medicine, Boston VA Medical Center)
• Paula Martin, PhD (Boston University School of Medicine, Boston VA Medical Center)
• Michael Ho, PHD (Boston University School of Medicine, Boston VA Medical Center)
• Peter Juni, MD, FESC (University of Toronto)
• Alexander Lin, PhD (Harvard Medical School)
• Corinne Fischer, MD (St Michael’s Hospital, University of Toronto)
• Jack Tuszynski, PhD (University of Alberta)
• Michael Staelens, PhD (Universty of Alberta)
• Aarat Kalra, PhD (Princeton University)
• David Tate, PhD (University of Utah)
• Elisabeth Wilde, PhD (University of Utah)
• Larry Carr, PhD (University of Utah)
• Michael Larson, PhD (Brigham Young University)
• Michael Hamblin, PhD (Harvard Medical School and University of Johannesburg)
• Praveen Arany, PhD, DDS (University at Bufallo)
• Jean Chen, PhD (Rotman Research Institute, University of Toronto)
• Linda Chao, PhD (University of California San Francisco)
• Julio C Rojas, MD, PhD (University of California San Francisco)
• Vincent Clark, PhD (University of New Mexico)
• Jay Sanguinetti, PhD (University of Arizona)
• Richard Gevirtz, PhD (Alliant International University)
• John Mitrofanis, PhD (University of Sydney)
• Shima Fardad, PhD (University of Kansas)
Management


Vielight Research Division

He is widely recognized as an expert on photobiomodulation (PBM), particularly in its application for brain functions and the effect on the immune system. He owns the largest number of worldwide issued and pending patents related to PBM as an individual.

Naz leads our covid-19 pivotal clinical trial and manages research projects in collaboration with the University of Alberta and Baycrest Hospital.
Given her background in biophysics, Naz’s passion aligns with Vielight’s goal of discovering how light energy could be used optimally to positively impact human physiology.

Gena manages Vielight’s research projects with various organizations for cognitive science, such as combining photobiomodulation with EEG.
Gena is passionate about neuroscience and a strong believer in the potential of photobiomodulation for improving mental acuity and brain health.

Mahroo is investigating the potential beneficial effects of photobiomodulation in elderly cognition and brain aging. She also researches the effects of photobiomodulation on neuro-oscillations.
Her interest in tissue engineering has lead her to find ways on how light energy could affect cellular mechanisms.

Dr. Abbaspour is involved in the research of the interactions of neurons with NIR energy and the corresponding effects on memory and mental acuity.
As a doctor, she is interested in the potential of photobiomodulation to address neurodegenerative diseases.

Presently, she manages and handles Vielight’s pivotal Alzheimer’s disease clinical trial – including protocol planning, recruitment and operations.
Janine utilizes her decade-long experience in the field of photobiomodulation to help further discoveries.
Independent Research Collaborators

She was a primary researcher in a groundbreaking n=49 TBI study, conducted at the University of Utah with ex-footballers, using the Vielight Neuro Gamma. The study is pending publication.

His research conducted with the Vielight Neuro Alpha provides a deeper level of understanding of the way living cells, cellular structures, and components such as microtubules respond to NIR photobiomodulation.

Dr. Naeser has published multiple TBI and CTE studies using Vielight Neuro technology on US Army Veterans.

Dr. Zomorrodi was the first in the world to publish a scientific paper showing the neuromodulatory effects of NIR light energy on the brain. The study used the Vielight Neuro Gamma. To date, the Vielight Neuro Gamma is the only commercially available brain photobiomodulation device to demonstrate neuromodulatory effects in a peer-reviewed published study in a high level journal.

Dr. Chao was the first to successfully combine fMRI imaging with brain photobiomodulation research to evidence neurophysiological changes in Alzheimer’s patients. She used the Vielight Neuro in her studies.

Dr. Tate was a primary researcher in a groundbreaking n=49 TBI study, conducted at the University of Utah with ex-footballers, using the Vielight Neuro Gamma. The study is pending publication.


Dr. Carr was enrolled in a CTE-study by Dr. Naeser and was inspired by the Vielight Neuro’s ability to greatly improve his CTE-symptoms, bringing him back to baseline. As such, he now leads several research initiatives for brain photobiomodulation, TBI and CTE at the U of Utah.

Dr. Chen is conducting fMRI-based studies with Vielight technology on the brain, to help discover optimal brain photobiomodulation parameters.

Dr. Hamblin co-authored the world’s first published study suggesting efficacy for brain photobiomodulation for Alzheimer’s Disease. The study featured Vielight Neuro technology.

Dr. Peña co-authored the first published study linking brain photobiomodulation to improved creativity. The study featured Vielight Neuro technology.
Marketing and Analytics Division

Mingyang conducted research at the McGill Additive Manufacturing Laboratory applying Laser Powder Bed Fusion technology on aircraft components. He has expertise in engineering design, materials characterization, and Lean Six Sigma.

Liyao is a certified Regulatory Affairs professional and holds the Regulatory Affairs Certificate (RAC-Device) issued by Regulatory Affairs Professional Society (RAPS).

She is a licensed professional engineer with over a decade of experience in mechanical engineering. Her expertise lies in project coordination and management, regulatory documentation, mechanical engineering design, mechanical property testing, and stress/fatigue analysis through FEA.

Rico’s primary passion is an interest in neuro-tech studies, research, and performance. His responsibilities at Vielight include matching our extensive line of products with the best solution to maximize potential in sports, cognitive support, or optimal systemic wellness & recovery.
Vielight Newsletter
As a small but dynamic company, we’re constantly innovating.
Interested in keeping up to date? Sign up for our newsletter.